The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2
Abstract
PURPOSE: Breast cancer in BRCA1 and BRCA2 gene-mutation carriers may differ from so-called sporadic breast cancer in clinical features and behavior. These potential differences may be of importance for the prevention, screening, and, ultimately, treatment of breast cancer in women with such germline mutations. Thus far, there have been very few studies on the survival of BRCA2-associated breast cancer patients. PATIENTS AND METHODS: We determined the disease-free and overall survival of 28 breast cancer patients from 14 consecutive families with eight different BRCA2 germline mutations. These patients' survival and tumor characteristics were compared with those of a control group of 112 sporadic breast cancer patients matched to them by age and year of diagnosis. RESULTS: The 5-year disease-free survival was 52% for each group (P = .91); the overall survival was 74% for BRCA2 carriers and 75% for sporadic cases (P = .50). At the time of diagnosis, tumors from the BRCA2 carriers were borderline significantly larger in comparison to the tumors in sporadic cases (P = .05), but axillary nodal status was not significantly different in the two groups (node-negativity, 63% v 52.8%, respectively; P = .34). With respect to steroid receptor status, BRCA2-associated tumors were more likely to be steroid receptor-positive, especially regarding progesterone receptor status (100% v 76.7% positive, respectively; P = .06). Stage-adjusted recurrence and death rates were nonsignificantly better for BRCA2 cases (hazard ratios of 0.84 and 0.59 [P = .61 and P = .19], respectively). In contrast, after 5 years, the rate of metachronous contralateral breast cancer in BRCA2 patients was 12% (v 2% in controls; P = .02). CONCLUSION: Patients with hereditary breast cancer due to BRCA2 have a similar prognosis when compared with age-matched sporadic breast cancer patients. Contrary to our previous observation regarding BRCA1-associated breast cancer, BRCA2 tumors tended to be steroid receptor-positive, instead of steroid receptor-negative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Self-citationSurvival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Jóhannsson, O. T., Ranstam, J., Borg, A., & Olsson, H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.397 · Cited by 254
Research works printed but not linked: 31
- 10.1126/science.7545954 · DOI · Paper page
- 10.1038/378789a0 · DOI · Paper page
- 10.1056/NEJM199705153362001 · DOI · Paper page
- 10.1086/301749 · DOI · Paper page
- 10.1200/JCO.1998.16.5.1969 · DOI · Paper page
- 10.1002/1097-0142(197112)28:6<1500::AID-CNCR2820280623>3.0.CO;2-D · doi:10.1002/1097-0142(197112)28:6<1500::aid-cncr2820280623>3.0.co;2-d
- 10.1126/science.2270482 · DOI · Paper page
- 10.1038/sj.bjc.6690235 · DOI
- 10.1023/A:1005853022804 · DOI
- 10.1016/S0140-6736(96)10109-4 · DOI · Paper page
- 10.1016/S0046-8177(98)90427-0 · DOI
- 10.1093/jnci/90.15.1138 · DOI · Paper page
- Lynch HT, Albano WA, Recabaren JA, et al: Survival in hereditary breast and colon cancer. JAMA 246:1197,1981, (letter) · DOI
- 10.1007/BF01806526 · DOI
- 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.0.CO;2-H · DOI
- 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
- 10.1016/S0140-6736(98)22005-8 · DOI
- 10.1016/S0167-8140(98)00023-1 · DOI
- 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N · DOI
- 10.1093/jnci/91.3.259 · DOI
- 10.1016/S0140-6736(05)79248-5 · DOI
- 10.1002/bjs.1800811038 · DOI
- 10.1200/JCO.1998.16.5.1642 · DOI · Paper page
- 10.1038/ng0596-117 · DOI · Paper page
- 10.1086/301885 · DOI · Paper page
- Osin P, Crook T, Powles T, et al: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 351:1487,1998, (letter) · DOI
- Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 229:424,1998-428, · DOI · Paper page
- 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W · DOI · Paper page
- 10.1016/S0959-8049(98)00248-2 · DOI
- 10.1093/jnci/90.18.1371 · DOI · Paper page
- 10.1097/00000658-197008000-00013 · doi:10.1097/00000658-197008000-00013
Cited by
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Self-citationOutcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1260 · Cited by 404
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Metadata
- Authors
- Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Wagner, A., Devilee, P., Halley, D. J. J., van den Ouweland, A. M. W., Meijers-Heijboer, E. J., & Klijn, J. G. M.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-11
- Volume
- 17
- Issue
- 11
- Pages
- 3396-3402
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1932411143
- Cited by
- 175
- References
- 3
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2. https://app.cochat.ai/papers/10.1200/jco.1999.17.11.3396
- The paper
- Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Wagner, A., Devilee, P., Halley, D. J. J., van den Ouweland, A. M. W., Meijers-Heijboer, E. J., & Klijn, J. G. M. (1999). Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.11.3396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.